MARKET

ADAP

ADAP

Adaptimmune Therapeutics Plc
NASDAQ
1.170
-0.010
-0.85%
After Hours: 1.170 0 0.00% 19:30 07/19 EDT
OPEN
1.190
PREV CLOSE
1.180
HIGH
1.230
LOW
1.130
VOLUME
904.08K
TURNOVER
0
52 WEEK HIGH
2.050
52 WEEK LOW
0.4200
MARKET CAP
299.01M
P/E (TTM)
-1.6060
1D
5D
1M
3M
1Y
5Y
1D
Buy Rating Affirmed for Adaptimmune on Revolutionary T-cell Therapy Prospects and Strong Sales Forecast
TipRanks · 2d ago
Adaptimmune Enhances Severance Benefits for Executives
TipRanks · 5d ago
Weekly Report: what happened at ADAP last week (0708-0712)?
Weekly Report · 6d ago
Weekly Report: what happened at ADAP last week (0701-0705)?
Weekly Report · 07/08 09:27
Adaptimmune: How The Story Is Shaping Up For The Latter Half Of 2024
Adaptimmune Therapeutics is a cell therapy-focused biotech focused on sarcoma management. The company has a cash runway of around 3 quarters and is in the late stages of development for their first treatment in cancers. I'm optimistic about the future of the company in the second half of 2024. Pipeline updates include progress on afami-cel and lete-cel for soft tissue sarcomas.
Seeking Alpha · 07/03 13:54
Weekly Report: what happened at ADAP last week (0624-0628)?
Weekly Report · 07/01 09:27
Weekly Report: what happened at ADAP last week (0617-0621)?
Weekly Report · 06/24 09:29
Weekly Report: what happened at ADAP last week (0610-0614)?
Weekly Report · 06/17 09:27
More
About ADAP
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. The Company is focused on providing cell therapies to people with cancer. Its engineered T-cell receptor (TCR) platform enables the engineering of T-cells to target and destroy cancers across multiple solid tumor types. Its cell therapy candidates include TCR T-cells and TruC T-cells. Its product candidates include afamitresgene autoleucel (afami-cel) and Lete-cel. The afamicel is a cell therapy that provides a treatment option for people with synovial sarcoma. The Company is in the process of transitioning lete-cel, which targets the NY-ESO antigen in people with synovial sarcoma and myxoid round cell liposarcoma (MRCLS). Its clinical pipeline includes SURPASS-III Phase II Trial with ADP-A2M4CD8 and SURPASS Phase I Trial with ADP-A2M4CD8. The Company’s most advanced pre-clinical programs are for T-cell therapies directed to the PRAME target (ADP-600) and to CD70 (ADP-520). ADAP-600 is an engineered TCR T-cell.

Webull offers Adaptimmune Therapeutics PLC - ADR stock information, including NASDAQ: ADAP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADAP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ADAP stock methods without spending real money on the virtual paper trading platform.